"10.1371_journal.pone.0127948","plos one","2015-06-08T00:00:00Z","Meher Majety; Leon P Pradel; Manuela Gies; Carola H Ries","Discovery Oncology, Roche Innovation Center Penzberg, Pharmaceutical Research and Early Development, Penzberg, Germany","Conceived and designed the experiments: MM. Performed the experiments: MM LPP MG. Analyzed the data: MM. Wrote the paper: MM CHR.","The authors have the following interests: This study was funded internally by Roche Diagnostics GmbH, the employer of all authors. The anti-IGF1R antibody (R1507) and the anti-cMet antibody (Onartuzumab) are described in the patents US7572897 titled “Antibodies against Insulin-like growth factor I receptor and uses thereof” and US7476724 titled “Humanized anti-cMet antibodies” respectively. There are no products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","06","Meher Majety","MM",4,TRUE,1,3,1,2,TRUE,TRUE,FALSE,0,NA,FALSE
